Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) FCF Margin (2021 - 2025)

Historic FCF Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 51.9%.

  • Rhythm Pharmaceuticals' FCF Margin rose 239400.0% to 51.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 62.6%, marking a year-over-year increase of 479600.0%. This contributed to the annual value of 87.51% for FY2024, which is 884000.0% up from last year.
  • As of Q3 2025, Rhythm Pharmaceuticals' FCF Margin stood at 51.9%, which was up 239400.0% from 48.07% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' FCF Margin's 5-year high stood at 45.05% during Q4 2024, with a 5-year trough of 95837.14% in Q1 2021.
  • For the 5-year period, Rhythm Pharmaceuticals' FCF Margin averaged around 6346.51%, with its median value being 213.78% (2023).
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' FCF Margin skyrocketed by 922484200bps in 2022, and later soared by 239400bps in 2025.
  • Rhythm Pharmaceuticals' FCF Margin (Quarter) stood at 2231.15% in 2021, then skyrocketed by 83bps to 386.79% in 2022, then soared by 69bps to 121.24% in 2023, then skyrocketed by 63bps to 45.05% in 2024, then dropped by -15bps to 51.9% in 2025.
  • Its FCF Margin was 51.9% in Q3 2025, compared to 48.07% in Q2 2025 and 123.38% in Q1 2025.